Miromatrix Medical Q3 EPS $(0.24) Misses $(0.21) Estimate, Sales $11.18K Down From $12.39K YoY

11/14/23 4:37:43 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $MIRO alert in real time by email

Miromatrix Medical (NASDAQ:MIRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 35.14 percent increase over losses of $(0.37) per share from the same period last year. The company reported $11.18 thousand in sales this quarter. This is a 9.83 percent decrease over sales of $12.39 thousand the same period last year.

Get the next $MIRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MIRO

Date	Price Target	Rating	Analyst
7/19/2021	$22.00	Buy	Craig Hallum

More analyst ratings

$MIRO
Press Releases

Fastest customizable press release news feed in the world

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem
12/13/23 9:15:00 AM ET
$MIRO
$UTHR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine
12/12/23 6:00:00 AM ET
$MIRO
$UTHR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Miromatrix Reports Third Quarter 2023 Results
EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to
11/14/23 4:05:00 PM ET
$MIRO
$UTHR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$MIRO
Financials

Live finance-specific insights

Miromatrix Reports Third Quarter 2023 Results
EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to
11/14/23 4:05:00 PM ET
$MIRO
$UTHR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and
8/14/23 4:01:00 PM ET
$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Miromatrix to Report Second Quarter 2023 Financial Results
EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l
7/25/23 4:01:00 PM ET
$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$MIRO
Market Insights

Live Market Insights

Miromatrix Medical Q3 EPS $(0.24) Misses $(0.21) Estimate, Sales $11.18K Down From $12.39K YoY
Miromatrix Medical (NASDAQ:MIRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 35.14 percent increase over losses of $(0.37) per share from the same period last year. The company reported $11.18 thousand in sales this quarter. This is a 9.83 percent decrease over sales of $12.39 thousand the same period last year.
11/14/23 4:37:43 PM ET
$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The S&P 500 also rose, gaining, 1.23% to 4,167.91. Check This Out: Top 4 Consumer Stocks That Could Blast Off This Quarter Leading and Lagging Sectors Communication services shares jumped by 2.3% on Monday. In trading on Monday, energy shares fell by 0.1%. Top Headline Western Digital Corp (NASDAQ:WDC) reported upbeat first-quarter results and announced a plan to separate its HDD and Flash businesses. Western Digital reported a first-quarter FY23 revenue decline of 26% year-on
10/30/23 3:06:49 PM ET
$ALZN
$COMM
$EAR
$LMDX
Biotechnology: Pharmaceutical Preparations
Health Care
Radio And Television Broadcasting And Communications Equipment
Technology
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ:EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ:VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ:HTCR)
10/30/23 1:55:55 PM ET
$ACLS
$ADD
$AEHR
$ALGN
Industrial Machinery/Components
Technology
Engineering & Construction
Consumer Discretionary

ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer
DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i
1/9/23 6:00:00 AM ET
$AXGN
$MIRO
$VRAY
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Miromatrix Appoints Jack Lake, M.D., as Medical Director
EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit
8/10/22 7:00:00 AM ET
$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Miromatrix Names Jim Douglas as New Chief Financial Officer
EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri
3/1/22 5:15:00 PM ET
$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Miromatrix Medical Q3 EPS $(0.24) Misses $(0.21) Estimate, Sales $11.18K Down From $12.39K YoY

Chat with this insight

Recent Analyst Ratings for
$MIRO

$MIRO
SEC Filings

SEC Form 15-12G filed by Miromatrix Medical Inc.

SEC Form EFFECT filed by Miromatrix Medical Inc.

$MIRO
Press Releases

Fastest customizable press release news feed in the world

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

Miromatrix Reports Third Quarter 2023 Results

$MIRO
Financials

Live finance-specific insights

Miromatrix Reports Third Quarter 2023 Results

Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

Miromatrix to Report Second Quarter 2023 Financial Results

$MIRO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Craig Hallum initiated coverage on Miromatrix Medical with a new price target

$MIRO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider United Therapeutics Corp claimed ownership of 27,419,228 shares (SEC Form 3)

Heine Lisa Wipperman returned 67,413 shares to the company, closing all direct ownership in the company (SEC Form 4)

Maag Peter returned 58,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

$MIRO
Market Insights

Live Market Insights